What lepodisiran is
Lepodisiran is a small interfering RNA (siRNA) developed by Eli Lilly. It targets the messenger RNA of the LPA gene, which carries the instructions for apolipoprotein(a), the protein that turns an ordinary LDL-like particle into lipoprotein(a), or Lp(a). By silencing that RNA in the liver, lepodisiran sharply reduces how much Lp(a) enters the blood. Lilly designed it for an extended duration of action, so it may need very infrequent dosing.
Why the target matters
Lp(a) levels are largely inherited, and genetic studies have linked higher Lp(a) to a greater risk of coronary disease. That human genetic evidence is the main reason several companies are developing Lp(a)-lowering drugs. See What Is Genomics? and the related profiles of olpasiran, pelacarsen, zerlasiran, and muvalaplin.
Clinical evidence
Phase 2: ALPACA
ALPACA randomized 320 participants with a median baseline Lp(a) of 253.9 nmol/L. Participants received lepodisiran at baseline and again at day 180, or placebo. Published in the New England Journal of Medicine in 2025:
| Dose | Placebo-adjusted change in Lp(a), day 60 to day 180 |
|---|---|
| 16 mg | −40.8% |
| 96 mg | −75.2% |
| 400 mg (pooled) | −93.9% |
Over the longer window from day 30 to day 360, participants who received 400 mg twice had a placebo-adjusted reduction of 94.8%, and those who received 400 mg once had 88.5%. Serious adverse events occurred in 35 participants, and none was judged by investigators to be related to lepodisiran or placebo. Generally mild injection-site reactions occurred in up to 12% of the highest-dose group.
Phase 3
| Trial | Purpose | Size | Status (registry) |
|---|---|---|---|
| ACCLAIM-Lp(a) | Whether lepodisiran reduces major adverse cardiovascular events in adults with elevated Lp(a) | Estimated 17,300 | Active, not recruiting; estimated primary completion March 2029 |
| ACCLAIM-CTA | Whether lepodisiran reduces coronary plaque, measured by CT angiography | Estimated 252 | Recruiting |
Scientific perspective
Lepodisiran achieves some of the deepest and longest-lasting Lp(a) reductions reported, from infrequent doses. Whether that prevents heart attacks and strokes has not been tested yet.
That question became much harder in 2026, when pelacarsen lowered Lp(a) by about 78% but did not reduce major cardiovascular events in its 8,323-patient outcomes trial. Lepodisiran differs in two potentially important ways: it lowers Lp(a) more, by over 90%, and its effect lasts much longer. Neither difference guarantees a different outcome. ACCLAIM-Lp(a) will be one of the largest tests of whether near-complete Lp(a) suppression translates into fewer cardiovascular events.
Development perspective
- Regulatory status: lepodisiran has no FDA approval. Approval to reduce cardiovascular risk would likely depend on a positive ACCLAIM-Lp(a) result.
- Timing: the registry estimates primary completion in March 2029. Amgen's similar siRNA, olpasiran, has an outcomes trial with an earlier estimated primary completion (March 2028), so the field is likely to see that result first.
- Historical benchmark: 57.8% of Phase 3 programs have historically reached an application, and about 52% have been approved. This average predates the pelacarsen result and does not account for it.
Competitive context
Lp(a) lowering is now a crowded field, with antisense drugs (pelacarsen), siRNAs (lepodisiran, olpasiran, zerlasiran), and an oral small molecule (Lilly's own muvalaplin). Lilly is unusual in developing two Lp(a) drugs with different mechanisms: an infrequent injection and a daily pill.
Development timeline
- Oct 20, 2022ALPACA Phase 2 trial begins (320 participants). Registry
- Mar 5, 2024ACCLAIM-Lp(a) Phase 3 cardiovascular outcomes trial begins. Registry
- Mar 30, 2025ALPACA results published: placebo-adjusted Lp(a) reduction of 93.9% from day 60 to day 180 with 400 mg. Peer-reviewed
- Jun 1, 2026ACCLAIM-CTA, a Phase 3 coronary plaque imaging trial, begins. Registry
- Sep 4, 2026Read-across: pelacarsen, a different Lp(a)-lowering drug, misses the primary endpoint of its Phase 3 outcomes trial. Company-reported
What could change the outlook
- The ACCLAIM-Lp(a) result. The registry estimates primary completion in March 2029, and estimated dates often move.
- Any amendment to ACCLAIM-Lp(a) after the pelacarsen result, such as a change in size, endpoint, or timing, which will be logged here if it appears in the registry.
- Results from Amgen's OCEAN(a)-Outcomes trial of olpasiran, a similar siRNA, which is expected to read out earlier and will inform expectations for lepodisiran.
- Coronary plaque imaging results from ACCLAIM-CTA, which could show whether deep Lp(a) lowering changes atherosclerosis.